NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.

[1]  M. Verstraete,et al.  A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.

[2]  P. Sassone-Corsi,et al.  Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1 , 2009, Science.

[3]  M. Stumvoll,et al.  Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  M. White,et al.  Insulin signaling meets mitochondria in metabolism , 2010, Trends in Endocrinology & Metabolism.

[5]  I. Rahman,et al.  Lysine deacetylation in ischaemic preconditioning: the role of SIRT1. , 2011, Cardiovascular research.

[6]  Ying Sun,et al.  Female Adult Mouse Cardiomyocytes Are Protected Against Oxidative Stress , 2010, Hypertension.

[7]  Wieland Kiess,et al.  Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.

[8]  J. Takahashi,et al.  Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD+ Biosynthesis , 2009, Science.

[9]  S. Cregan,et al.  Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase* , 2007, Journal of Biological Chemistry.

[10]  M. Okada,et al.  Visfatin causes endothelium-dependent relaxation in isolated blood vessels. , 2009, Biochemical and biophysical research communications.

[11]  K. Lillemoe,et al.  Estrogen receptor beta mediates acute myocardial protection following ischemia. , 2008, Surgery.

[12]  M. Marescotti,et al.  A Visfatin Promoter Polymorphism Is Associated with Low‐Grade Inflammation and Type 2 Diabetes , 2006, Obesity.

[13]  J. Odeberg,et al.  Serum matrix metalloproteinase‐3 concentration is influenced by MMP‐3 −1612 5A/6A promoter genotype and associated with myocardial infarction , 2005, Journal of internal medicine.

[14]  J. Milbrandt,et al.  Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. , 2007, Cell metabolism.

[15]  Swneke D. Bailey,et al.  Common Polymorphisms in the Promoter of the Visfatin Gene (PBEF1) Influence Plasma Insulin Levels in a French-Canadian Population , 2006, Diabetes.

[16]  Wei Li,et al.  p53 expression in human carotid atheroma is significantly related to plaque instability and clinical manifestations. , 2010, Atherosclerosis.

[17]  S. Imai.  A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. , 2010, Pharmacological research.

[18]  T. Church,et al.  Skeletal muscle NAMPT is induced by exercise in humans. , 2010, American journal of physiology. Endocrinology and metabolism.

[19]  B. Gigante,et al.  The myeloperoxidase gene and its influence on myocardial infarction in a Swedish population: protective role of the −129A allele in women , 2009, Coronary artery disease.

[20]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[21]  S. Tonstad,et al.  Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque Destabilization , 2007, Circulation.

[22]  Meijing Wang,et al.  Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[23]  M. Al-Omran,et al.  Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. , 2009, American journal of physiology. Endocrinology and metabolism.

[24]  A. Levine,et al.  Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Brandt,et al.  A novel MEK2/PI3Kδ pathway controls the expression of IL‐1 receptor antagonist in IFN‐β‐activated human monocytes , 2010, Journal of leukocyte biology.

[26]  Mark A Sussman,et al.  Myocardial Akt Activation and Gender: Increased Nuclear Activity in Females Versus Males , 2001, Circulation research.

[27]  E. Murphy,et al.  Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. , 2009, American journal of physiology. Heart and circulatory physiology.

[28]  G. Remuzzi,et al.  Disruption of the Ang II type 1 receptor promotes longevity in mice. , 2009, The Journal of clinical investigation.

[29]  P. Aukrust,et al.  Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages , 2011, European journal of clinical investigation.

[30]  D. Yellon,et al.  Adipocytokines, cardiovascular pathophysiology and myocardial protection. , 2011, Pharmacology & therapeutics.

[31]  Mark A Sussman,et al.  Nuclear and mitochondrial signalling Akts in cardiomyocytes. , 2008, Cardiovascular research.

[32]  Dan Shao,et al.  Nicotinamide Phosphoribosyltransferase Regulates Cell Survival Through NAD+ Synthesis in Cardiac Myocytes , 2009, Circulation research.

[33]  D. Yellon,et al.  The novel adipocytokine visfatin exerts direct cardioprotective effects , 2008, Journal of cellular and molecular medicine.

[34]  R. Karas,et al.  17&bgr;-Estradiol Reduces Cardiomyocyte Apoptosis In Vivo and In Vitro via Activation of Phospho-Inositide-3 Kinase/Akt Signaling , 2004, Circulation research.

[35]  Dong Liu,et al.  Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans , 2009, Clinical endocrinology.

[36]  S. Chierchia,et al.  Gender differences in the cardiovascular effects of sex hormones , 2010, Fundamental & clinical pharmacology.

[37]  G. Caimi,et al.  Role of genetic polymorphisms in myocardial infarction at young age. , 2010, Clinical hemorheology and microcirculation.

[38]  Zhijian Yang,et al.  A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease , 2011, Molecular Biology Reports.

[39]  C. Hogstedt,et al.  Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the S heep study , 1999 .